Drug interactions involving human immunodeficiency virus protease inhibitors are common due to their inhibition of the cytochrome P450 3A4 isoenzyme. We describe the case of an HIV-infected patient treated with ritonavir-boosted darunavir who developed cushingoid features following an intra-articular injection of triamcinolone acetate. We review the probable mechanism for this interaction and describe similar cases of Cushing syndrome in patients receiving concomitant ritonavir and triamcinolone.
American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee (updated February 2005). http://www.rheumatology.org/practice/clinical/guidelines/oa-mgmt.asp (2000, accessed 12 September 2012).
2.
BykerkVPAkhavanPHazlewoodGSSchieirODooleyAHarouiB. Canadian rheumatology association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol2012; 39: 1559–1582.
3.
Triamcinolone acetonide. DRUGDEX System. Greenwood Village, CO: Thomson Micromedex. www.thomsonhc.com (accessed 12 September 2012).
4.
ZhouSFZueCCYuXQLiCWangG. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit2007; 29: 687–710.
5.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 27 March 2012. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed 12 September 2012).
6.
ZeldinRKPetruschkeRA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother2004; 53: 4–9.
7.
DerendorfHMöllmannHGrünerAHaackDGeselbyG. Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration. Clin Pharmacol Ther1986; 39(3): 313–317.
8.
JansenTLTAvan RoonEN. Four cases of a secondary Cushingoid state following local triamcinolone acetonide (Kenacort®) injection. Neth J Med2002; 60(3): 151–153.
9.
O’SullivanMMRumfeldWRJonesMKWilliamsBD. Cushing’s syndrome with suppression of the hypothalamic-pituitary–adrenal axis after intra-articular steroid injections. Ann Rheum Dis1985; 44: 561–563.
10.
BusseKHFormentiniEAlfaroRMKovacsJAPenzakSR. Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals. J Acquir Immune Defic Syndr2008; 48: 561–566.
11.
FoisyMMYakiwchukEMKChiuISinghAE. Adrenal suppression and Cushing’s syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. HIV Med2008; 8: 389–396.
12.
FrankelJKPackerCD. Cushing’s syndrome due to antiretroviral-budesonide interaction. Ann Pharmacother2011; 45: 823–824.
13.
DanaherPJSalsburyTLDelmarJA. Metabolic derangement after injection of triamcinolone into the hip of an HIV-infected patient receiving ritonavir. Orthopedics2009; 32: 450–452.
14.
DortKPadiaSWispelweyBMooreCC. Adrenal suppression due to an interaction between ritonavir and injected triamcinolone: a case report. AIDS Res Ther2009; 6: 10–13.
15.
RamanathanRPauAKBusseKHZemskovaMNeimanLKwanR. Iatrogenic Cushing’s syndrome following epidural triamcinolone in an HIV-1 infected patient undergoing therapy with ritonavir-lopinavir. Clin Infect Dis2008; 47: e97–e99.
16.
YombiJCMaiterDBelkhirLNzeusseuAVandercamB. Iatrogenic Cushing’s syndrome and secondary adrenal insufficiency after a single intra-articular administration of triamcinolone acetonide in HIV-infected patients treated with ritonavir. Clin Rheumatol2008; 27(Suppl. 2): S79–S82.
17.
AlbertNEKaziSSantoroJDoughertyR. Ritonavir and epidural triamcinolone as a cause of iatrogenic Cushing's syndrome. Am J Med Sci2012; 344(1): 72–74.
18.
Marshall NJ, Gurazada K, Bouloux P, Khoo B and Johnson MA. Secondary adrenal suppression and Cushing’s syndrome caused by ritonavir-boosted effects of inhaled fluticasone, injected triamcinolone, and topical clobetasol: a case series. In: Presented at Society for Endocrinology BES 2012, Harrogate, UK, 18–22 March 2012 (Poster).
19.
LevineDAnanthakrishnanSGargA. Iatrogenic Cushing syndrome after a single intramuscular corticosteroid injection and concomitant protease inhibitor therapy. J Am Acad Dermatol2011; 65(4): 877–878.
20.
GriersonMJHarrastMA. Iatrogenic Cushing syndrome after epidural steroid injections for lumbar radiculopathy in an HIV-infected patient treated with ritonavir: a case report highlighting drug interactions for spine interventionalists. Phys Med Rehabil2012; 4(3): 234–237.
21.
HornJRHanstenPDChanLN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother2007; 41: 674–680.
22.
NaranjoCABustoUSellersEMSandorPRuizIRobertsEA. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981; 30: 239–245.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
